Alternative Data for Gyre Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,467 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Gyre Therapeutics
None
| Price | $7.81 |
| Target Price | Sign up |
| Volume | 156,469 |
| Market Cap | $782M |
| Year Range | $6.65 - $8.87 |
| Dividend Yield | 0% |
| PE Ratio | 203 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 12 - GlobeNewswire |
|
Gyre Therapeutics to acquire Cullgen in $300M all-stock transactionMarch 3 - Yahoo Entertainment |
|
 |
Earnings Scheduled For March 12, 2026March 11 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 31M | 1.6M | 29M | 3.6M | 8.3M | 0.030 |
| Q2 '25 | 27M | 1.2M | 26M | 440,000 | 2.8M | 0.002 |
| Q1 '25 | 22M | 890,000 | 21M | 2.7M | 2.8M | 0.004 |
| Q4 '24 | 28M | 1.2M | 27M | -99,000 | 1.1M | -0.001 |
| Q3 '24 | 25M | 960,000 | 25M | 1.1M | 4.7M | 0.013 |
Insider Transactions View All
| Ma Songjiang filed to sell 2,806,084 shares at $10.1. May 29 '25 |
| Ma Songjiang filed to sell 2,806,642 shares at $10.3. May 29 '25 |
| Ma Songjiang filed to sell 2,808,642 shares at $10.2. May 27 '25 |
| Ma Songjiang filed to sell 2,808,824 shares at $11. May 27 '25 |
| Ma Songjiang filed to sell 2,810,824 shares at $10.8. May 22 '25 |
Similar companies
Read more about Gyre Therapeutics (GYRE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Gyre Therapeutics
The Market Cap of Gyre Therapeutics is $782M.
As of today, Gyre Therapeutics' PE (Price to Earnings) ratio is 203.
Currently, the price of one share of Gyre Therapeutics stock is $7.81.
The GYRE stock price chart above provides a comprehensive visual representation of Gyre Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gyre Therapeutics shares. Our platform offers an up-to-date GYRE stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Gyre Therapeutics (GYRE) does not offer dividends to its shareholders. Investors interested in Gyre Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Gyre Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
